TScan Therapeutics Q2 2024 GAAP EPS $(0.28) Beats $(0.29) Estimate, Sales $536.000K May Not Be Comparable To $2.419M Estimate
Portfolio Pulse from Benzinga Newsdesk
TScan Therapeutics reported a Q2 2024 GAAP EPS of $(0.28), beating the estimate of $(0.29). However, their sales of $536,000 may not be comparable to the $2.419 million estimate.
August 12, 2024 | 11:20 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
TScan Therapeutics reported a Q2 2024 GAAP EPS of $(0.28), which is better than the estimated $(0.29). However, their sales of $536,000 may not be comparable to the $2.419 million estimate.
The better-than-expected EPS is a positive sign, but the sales figure discrepancy introduces uncertainty. This mixed result may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100